Table 1 Most common benign and malignant types of neoplasms in different studies.

Distribution benign/malignant

B: 41.9%

M: 58.1%

B: 48.2%

M: 52.8%

B: 53.4%

M: 46.6%

B: 69%

M: 31%

Top 3 benign

Pct of all skin tumours

(Pct of all benign tumours)

Basal cell tumour 12.0% (20.7%)

Perianal gl. adenomas 8.3% (19.8%)

Histiocytoma 7.8% (18.6%)

Histiocytoma 14.0% (29.0%)

Lipoma 6.0% (12.4%)

Basal cell epithelioma 5.5% (11.4%)

Hepato gl. adenoma 9.8% (18.3%)

Lipoma 5.7% (10.8%)

Histiocytoma 5.7% (10.8%)

Epidermal cysts 12.7% (18.3%)

Lipoma 11.4% (16.4%)

Histiocytoma 7.5% (10.8%)

Top 3 malignant

Pct of total skin (pct of all malignant skin tumours)

MCT 17.6% (30.3%)

STS 8.5% (14.6%)

Melanoma 6.8% (11.7%)

MCT 16.1% (31.1%)

STS 14.4% (27.8%)

SCC 6.9% (13.3%)

MCT 13.8% (29.6%)

STS 10.3% (22.2%)

Basal cell carcinoma 4.0% (8.6%)

MCT 8.8% (28.7%)

STS 3.3% (10.9%)

Apocrine adenocarcinoma 3.1% (10.0%)

Registry

Norway

[1]

#, N = 7401

South Africa

[18]

#; N = 903

USA

[3]

#, N = 277

Distribution benign/malignant

M: 22%

B: 54.4%

M: 45.6%

M: 100%

Top 3 benign

Pct of all skin tumours

(Pct of all benign tumours)

Epidermal adenoma 22.7% (29.2%)

Lipoma 13.6% (17.4%)

Histiocytoma 13.3% (17.1%)

Basal cell tumour 18.8% (34.6%)

Perineal gland adenoma 13.4% (24.6%)

Sebaceous gland adenomas and cysts 6.1% (11.2%)

-

Top 3 malignant

Pct of total skin (pct of all malignant skin tumours)

MCT 10.0 (45.4%)

STS 4.3% (19.6%)

Malignant epidermal tumours 3.4% (15.4%)

SCC 16.4% (35.9%)

Melanoma 11.4% (25.0%)

MCT 8.9% (19.4%)

MCT (27%)

Adenocarcinoma (26%)

Melanoma (22%)